Stockscreener 앱 받기
3.51
3.85%
0.13
시간 외 거래:
3.51
Atea Pharmaceuticals Inc 주식(AVIR)의 최신 뉴스
What candlestick patterns are forming on Atea Pharmaceuticals Inc.Daily Profit Watch With Forecast Confidence - Newser
Institutional scanner results for Atea Pharmaceuticals Inc.AI-Based Reversal Point Prediction Signal - Newser
Does Atea Pharmaceuticals Inc. fit your quant trading modelFree Triple Return Setup with Risk Control - Newser
Using data tools to time your Atea Pharmaceuticals Inc. exitFree Swing Setup With Technical Confirmation - Newser
What earnings revisions data tells us about Atea Pharmaceuticals Inc.Strong Buy Signal Summary with Entry Zone - Newser
Atea Pharmaceuticals Inc. stock daily chart insightsEntry Timing Tracker with Alert Accuracy - Newser
Published on: 2025-08-11 00:21:03 - Newser
How to build a custom watchlist for Atea Pharmaceuticals Inc.Free Reversal Alert Based on RSI Indicator - Newser
Atea Pharmaceuticals Inc. stock outlook for YEARSwing Entry Insight With Forecast Accuracy - Newser
Detecting support and resistance levels for Atea Pharmaceuticals Inc.Intraday Signal Forecast for Fast Traders - Newser
Signal strength of Atea Pharmaceuticals Inc. stock in tech scannersEarnings Report Summary with Market Impact - Newser
Visualizing Atea Pharmaceuticals Inc. stock with heatmapsBreakout Watcher with Entry and Exit Alerts - Newser
Why Atea Pharmaceuticals Inc. stock attracts strong analyst attentionMinimal Risk Growth Investment Opportunity Analysis - Newser
Will Atea Pharmaceuticals Inc. price bounce be sustainableSmart Swing Picks with Confirmed Signals - Newser
Is Atea Pharmaceuticals Inc. forming a bottoming baseAI Trading Forecast Based on Big Data - Newser
Atea Pharmaceuticals (AVIR): A High-Growth HCV Play with Clinical and Financial Momentum - AInvest
Is Atea Pharmaceuticals Inc. meeting your algorithmic filter criteriaReal Time Alert System for Market Moves - Newser
Atea Pharmaceuticals (NASDAQ:AVIR) Stock Rating Lowered by Wall Street Zen - Defense World
When is the best time to exit Atea Pharmaceuticals Inc.Momentum-Based Prediction for Quick Returns - Newser
Atea Pharmaceuticals Q2 2025 slides: HCV program advances with Phase 3 trials underway - Investing.com Canada
Atea (AVIR) Q2 Loss Narrows 8% - AOL.com
Atea Pharmaceuticals Advances in HCV Treatment Development - TipRanks
Custom watchlist performance reports with Atea Pharmaceuticals Inc.Buy and Exit Strategy Based on Momentum - Newser
Atea Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Atea Pharmaceuticals Inc. Company’s Quarterly Earnings Growth: What the Numbers SayEarnings Based Stock Performance Forecast - Newser
Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
What makes Atea Pharmaceuticals Inc. stock price move sharplyTrade Flow Monitor with Volume Tracker - Newser
Atea Pharmaceuticals (AVIR) Expected to Announce Earnings on Thursday - Defense World
Is Atea Pharmaceuticals Inc. a Top Dividend Stock to Watch in 2025Swing Trade Watchlist with Entry Zones - Newser
Atea Pharmaceuticals Inc expected to post a loss of 45 cents a shareEarnings Preview - TradingView
Atea Pharmaceuticals Inc. stock volume spike explainedSwing Trade Signal and Price Prediction - Newser
Atea Pharmaceuticals Inc. stock trendline breakdownOversold Reversal Picks with Buy Zone - Newser
1.02%
3.70%
자본화:
|
볼륨(24시간):